share_log

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

吉利德科學 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/09 05:20

Moomoo AI 已提取核心訊息

Gilead Sciences reported total revenues of $7.0 billion for Q2 2024, up 5% year-over-year, driven by strong performance in HIV, Oncology and Liver Disease portfolios. HIV product sales increased 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenues rose 15% to $841 million, with Trodelvy sales growing 23% to $320 million and Cell Therapy sales up 11% to $521 million.Net income increased 55% to $1.6 billion and diluted EPS rose to $1.29, compared to $1.0 billion and $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues, partially offset by increased unrealized losses on equity securities. Product gross margin remained stable at 77.7%.For the first half of 2024, the company recorded a net loss of $2.6 billion, primarily due to a $3.9 billion charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge for NSCLC assets. The company maintained strong liquidity with $2.8 billion in cash and equivalents, despite significant investments in acquisitions and R&D during the period.
Gilead Sciences reported total revenues of $7.0 billion for Q2 2024, up 5% year-over-year, driven by strong performance in HIV, Oncology and Liver Disease portfolios. HIV product sales increased 3% to $4.7 billion, led by Biktarvy's 8% growth to $3.2 billion. Oncology revenues rose 15% to $841 million, with Trodelvy sales growing 23% to $320 million and Cell Therapy sales up 11% to $521 million.Net income increased 55% to $1.6 billion and diluted EPS rose to $1.29, compared to $1.0 billion and $0.83 in Q2 2023. The improvement was driven by lower operating expenses and higher revenues, partially offset by increased unrealized losses on equity securities. Product gross margin remained stable at 77.7%.For the first half of 2024, the company recorded a net loss of $2.6 billion, primarily due to a $3.9 billion charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge for NSCLC assets. The company maintained strong liquidity with $2.8 billion in cash and equivalents, despite significant investments in acquisitions and R&D during the period.
吉利德科學報告稱2024年第二季度總收入爲70億美金，同比增長5%，這一增長得益於HIV、腫瘤學和肝病產品組合的強勁表現。HIV產品銷售增長3%，達到47億美金，其中Biktarvy增長8%，達到32億美金。腫瘤學收入上漲15%，達到84100萬美金，Trodelvy銷售增長23%，達到32000萬美金，電芯治療銷售增長11%，達到52100萬美金。凈利潤增加55%，達到16億美金，攤薄後每股收益上升至1.29美金，相較於2023年第二季度的10億美金和0.83美金有所改善。改善的主要原因是營業費用降低和收入增加，部分被股權證券未實現損失增加所抵消。產品毛利率保持在77.7%。在2024年上半年，公司錄得淨虧損26億美金，主要由於與CymaBay收購相關的39億美金費用以及與NSCLC資產相關的24億美金的知識產權和研發減值費用。儘管在此期間進行了大量的收購和研發投資，公司仍保持強勁的流動性，現金及現金等價物達28億美金。
吉利德科學報告稱2024年第二季度總收入爲70億美金，同比增長5%，這一增長得益於HIV、腫瘤學和肝病產品組合的強勁表現。HIV產品銷售增長3%，達到47億美金，其中Biktarvy增長8%，達到32億美金。腫瘤學收入上漲15%，達到84100萬美金，Trodelvy銷售增長23%，達到32000萬美金，電芯治療銷售增長11%，達到52100萬美金。凈利潤增加55%，達到16億美金，攤薄後每股收益上升至1.29美金，相較於2023年第二季度的10億美金和0.83美金有所改善。改善的主要原因是營業費用降低和收入增加，部分被股權證券未實現損失增加所抵消。產品毛利率保持在77.7%。在2024年上半年，公司錄得淨虧損26億美金，主要由於與CymaBay收購相關的39億美金費用以及與NSCLC資產相關的24億美金的知識產權和研發減值費用。儘管在此期間進行了大量的收購和研發投資，公司仍保持強勁的流動性，現金及現金等價物達28億美金。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿瑪琳
    AMRN
    -- 0.612
    賽諾菲安萬特
    SNY
    -- 54.500
    艾伯維公司
    ABBV
    -- 192.870
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！